Literature DB >> 29968152

The Future of IL-1 Targeting in Kidney Disease.

Baris Afsar1, Adrian Covic2, Alberto Ortiz3, Rengin Elsurer Afsar4, Mehmet Kanbay5.   

Abstract

Interleukin (IL)-1α and IL-1β are proinflammatory cytokines that play a role in many diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and periodic inflammatory syndromes, including familial Mediterranean fever and Muckle-Wells syndrome. Drugs targeting IL-1 such as recombinant IL-1Ra (anakinra), neutralizing anti-IL-1β antibodies (canakinumab) and IL-1β traps (rilonacept) are in clinical use to treat these diseases. Additionally, experimental evidence suggests a role of IL-1 in kidney disease and hypertension and targeting IL-1 showed promising results in high cardiovascular risk patients, hemodialysis and renal transplantation patients. We now summarize knowledge on the potential role of IL-1 targeting in patients with kidney disease.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29968152     DOI： 10.1007/s40265-018-0942-2

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  111 in total

1.  A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.

Authors:  Raphaela Goldbach-Mansky; Sharukh D Shroff; Mildred Wilson; Christopher Snyder; Sara Plehn; Beverly Barham; Tuyet-Hang Pham; Frank Pucino; Robert A Wesley; Joanne H Papadopoulos; Steven P Weinstein; Scott J Mellis; Daniel L Kastner
Journal:  Arthritis Rheum       Date:  2008-08

Review 2.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

Review 3.  Anakinra as an interleukin 1 receptor antagonist, complicated genetics and molecular impacts--from the point of view of mouse genomics.

Authors:  Yanhong Cao; Yan Jiao; Lishi Wang; Yue Huang; Arnold Postlethwaite; John Stuart; Andy Kang; Robert W Williams; Weikuan Gu
Journal:  Int Immunopharmacol       Date:  2012-03-14       Impact factor: 4.932

4.  IL-1β receptor antagonist reduces inflammation in hemodialysis patients.

Authors:  Adriana M Hung; Charles D Ellis; Ayumi Shintani; Cindy Booker; T Alp Ikizler
Journal:  J Am Soc Nephrol       Date:  2011-02-10       Impact factor: 10.121

5.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.

Authors:  D B Carter; M R Deibel; C J Dunn; C S Tomich; A L Laborde; J L Slightom; A E Berger; M J Bienkowski; F F Sun; R N McEwan
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

6.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors:  Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal:  Arthritis Rheum       Date:  2008-08

7.  Pharmacokinetics of anakinra in subjects with different levels of renal function.

Authors:  Bing-Bing Yang; Sharon Baughman; John T Sullivan
Journal:  Clin Pharmacol Ther       Date:  2003-07       Impact factor: 6.875

Review 8.  Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.

Authors:  Jasmin B Kuemmerle-Deschner; Iris Haug
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-12       Impact factor: 5.346

9.  The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.

Authors:  Rieke Alten; Hermann Gram; Leo A Joosten; Wim B van den Berg; Joachim Sieper; Siegfrid Wassenberg; Gerd Burmester; Piet van Riel; Maria Diaz-Lorente; Gerardus J M Bruin; Thasia G Woodworth; Christiane Rordorf; Yannik Batard; Andrew M Wright; Thomas Jung
Journal:  Arthritis Res Ther       Date:  2008-06-05       Impact factor: 5.156

Review 10.  The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases.

Authors:  Carlos de Torre-Minguela; Pablo Mesa Del Castillo; Pablo Pelegrín
Journal:  Front Immunol       Date:  2017-01-27       Impact factor: 7.561
View more
  6 in total

1.  Transcriptome analysis of primary chicken cells infected with infectious bronchitis virus strain K047-12 isolated in Korea.

Authors:  Rangyeon Lee; Ji Seung Jung; Ji-In Yeo; Hyuk Moo Kwon; Jeongho Park
Journal:  Arch Virol       Date:  2021-06-05       Impact factor: 2.685

2.  A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosis.

Authors:  Michael Boehm; Eva Nora Bukosza; Nicole Huttary; Rebecca Herzog; Christoph Aufricht; Klaus Kratochwill; Christoph A Gebeshuber
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

3.  A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease.

Authors:  Mehmet Kanbay; Aslihan Yerlikaya; Alan A Sag; Alberto Ortiz; Masanari Kuwabara; Adrian Covic; Andrzej Wiecek; Peter Stenvinkel; Baris Afsar
Journal:  Clin Kidney J       Date:  2019-09-18

4.  Interleukin 1 beta-induced calcium signaling via TRPA1 channels promotes mitogen-activated protein kinase-dependent mesangial cell proliferation.

Authors:  Hitesh Soni; Ravi Kumar; Praghalathan Kanthakumar; Adebowale Adebiyi
Journal:  FASEB J       Date:  2021-07       Impact factor: 5.834

Review 5.  Key Factor Regulating Inflammatory Microenvironment, Metastasis, and Resistance in Breast Cancer: Interleukin-1 Signaling.

Authors:  Fengjie Liu; Lihong Li; Meng Lan; Tengteng Zou; Zhaodi Kong; Tiange Cai; Xiao Yu Wu; Yu Cai
Journal:  Mediators Inflamm       Date:  2021-09-23       Impact factor: 4.711

6.  Effect of Berberine on Hyperuricemia and Kidney Injury: A Network Pharmacology Analysis and Experimental Validation in a Mouse Model.

Authors:  Qiaoping Li; Ziwei Huang; Defu Liu; Jingna Zheng; Jianhui Xie; Jiannan Chen; Huifang Zeng; Ziren Su; Yucui Li
Journal:  Drug Des Devel Ther       Date:  2021-07-27       Impact factor: 4.162
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.